Kathryn J. Leyva

Dr. Kathryn J. Leyva

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EHElizabeth Hull
Elizabeth Hull
MMMcKale Montgomery
McKale Montgomery
KLKathryn J. Leyva
Kathryn J. Leyva
Emerging evidence suggests that the enzymes in the biosynthetic pathway for the synthesis of heparan sulfate moieties of heparan sulfate proteoglycans (HSPGs) are epigenetically regulated at many levels. As the exact composition of the heparan sulfate portion of the resulting HSPG molecules is critical to the broad spectrum of biological processes involved in oncogenesis, the epigenetic regulation of heparan sulfate biosynthesis has far-reaching effects on many cellular activities related to cancer progression. Given the current focus on developing new anti-cancer therapeutics focused on epigenetic targets, it is important to understand the effects that these emerging therapeutics may have on the synthesis of HSPGs as alterations in HSPG composition may have profound and unanticipated effects. As an introduction, this review will briefly summarize the variety of important roles which HSPGs play in a wide-spectrum of cancer-related cellular and physiological functions and then describe the biosynthesis of the heparan sulfate chains of HSPGs, including how alterations observed in cancer cells serve as potential biomarkers. This review will then focus on detailing the multiple levels of epigenetic regulation of the enzymes in the heparan sulfate synthesis pathway with a particular focus on regulation by miRNA and effects of epigenetic therapies on HSPGs. We will also explore the use of lectins to detect differences in heparan sulfate composition and preview their potential diagnostic and prognostic use in the clinic.

1 July 2013 in Experimental Cell Research
Verified
Journal Article
Closed access
TMTimothy M. McDonald
Timothy M. McDonald
APAgnes S. Pascual
Agnes S. Pascual
CUChandana K. Uppalapati
Chandana K. Uppalapati
KCKimbal E. Cooper
Kimbal E. Cooper
KLKathryn J. Leyva
Kathryn J. Leyva
EHElizabeth Hull
Elizabeth Hull

28 October 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
BFBrianna M. Flores
Brianna M. Flores
CUChandana Uppalapati
Chandana Uppalapati
APAgnes S. Pascual
Agnes S. Pascual
AVAlan Vong
Alan Vong
MBMargaux A. Baatz
Margaux A. Baatz
EHElizabeth Hull
Elizabeth Hull
The coordination of zinc by histone deacetylase inhibitors (HDACi), altering the bioavailability of zinc to histone deacetylases (HDACs), is key to HDAC enzyme inhibition. However, the ability of zinc binding groups (ZBGs) to alter intracellular free Zn+2 levels, which may have far-reaching effects, has not been explored. Using two HDACis with different ZBGs, we documented shifts in intracellular free Zn+2 concentrations that correlate with subsequent ROS production. Next, we assayed refolding and reactivation of the R175H mutant p53 protein in vitro to provide greater biological context as the activity of this mutant depends on cellular zinc concentration. The data presented demonstrates the differential activity of HDACi in promoting R175H response element (RE) binding. After cells are treated with HDACi, there are differences in R175H mutant p53 refolding and reactivation, which may be related to treatments. Collectively, we show that HDACis with distinct ZBGs differentially impact the intracellular free Zn+2 concentration, ROS levels, and activity of R175H; therefore, HDACis may have significant activity independent of their ability to alter acetylation levels. Our results suggest a framework for reevaluating the role of zinc in the variable or off-target effects of HDACi, suggesting that the ZBGs of HDAC inhibitors may provide bioavailable zinc without the toxicity associated with zinc metallochaperones such as ZMC1.

12 March 2021 in Cell Biology International
Verified
Journal Article
Open access
PDF file
APAgnes S. Pascual
Agnes S. Pascual
JRJose L. Rapanan
Jose L. Rapanan
CUChandana K. Uppalapati
Chandana K. Uppalapati
KCKimbal E. Cooper
Kimbal E. Cooper
KLKathryn J. Leyva
Kathryn J. Leyva
EHElizabeth Hull
Elizabeth Hull
There is a growing controversy about the role of the epithelial to mesenchymal transition (EMT) in the fibrosis associated with chronic disease. Recent studies suggest that it is not the EMT transcriptional program but differentiation of progenitor cells, response to chronic inflammation, or some combination of both which cause the appearance of fibroblasts and the production of extracellular matrix. To address this issue, we study the EMT process in the zebrafish keratocytes which migrate from primary explants of epithelial tissue as these cells are both terminally differentiated and able to divide. To firmly place this EMT process in the context of other systems, we first demonstrate that the zebrafish keratocyte EMT process involves nuclear accumulation of twist and snail/slug transcription factors as part of a TGFβR‐mediated EMT process. As assessed by expression and localization of EMT transcription factors, the zebrafish keratocyte EMT process is reversed by the addition of Rho activated kinase (ROCK) in combination with TGFβR inhibitors. The complete cycle of EMT to MET observed in this system links these in vitro results more closely to the process of wound healing in vivo. However, the absence of observable activation of EMT transcription factors when keratocytes are cultured on compliant substrata in a TGFβ1‐containing medium suggests that ROCK signaling, initiated by tension within the sheet, is an essential contributor to the EMT process. Most importantly, the requirement for ROCK activation by culturing on non‐compliant substrata suggests that EMT in these terminally differentiated cells would not occur in vivo.

Verified
Journal Article
Open access
PDF file
CPChristopher S. Pulford
Christopher S. Pulford
CUChandana Uppalapati
Chandana Uppalapati
MMMcKale Montgomery
McKale Montgomery
RARichard L. Averitte
Richard L. Averitte
EHElizabeth Hull
Elizabeth Hull
KLKathryn J. Leyva
Kathryn J. Leyva
While most cases of cutaneous squamous cell carcinoma (cSCC) are benign, invasive cSCC is associated with higher mortality and is often more difficult to treat. As such, understanding the factors that influence the progression of cSCC are important. Aggressive cancers metastasize through a series of evolutionary changes, collectively called the epithelial-to-mesenchymal transition (EMT). During EMT, epithelial cells transition to a highly mobile mesenchymal cell type with metastatic capacities. While changes in expression of TGF-β, ZEB1, SNAI1, MMPs, vimentin, and E-cadherin are hallmarks of an EMT process occurring within cancer cells, including cSCC cells, EMT within tissues is not an “all or none” process. Using patient-derived cSCC and adjacent normal tissues, we show that cells within individual cSCC tumors are undergoing a hybrid EMT process, where there is variation in expression of EMT markers by cells within a tumor mass that may be facilitating invasion. Interestingly, cells along the outer edges of a tumor mass exhibit a more mesenchymal phenotype, with reduced E-cadherin, β-catenin, and cytokeratin expression and increased vimentin expression. Conversely, cells in the center of a tumor mass retain a higher expression of the epithelial markers E-cadherin and cytokeratin and little to no expression of vimentin, a mesenchymal marker. We also detected inverse expression changes in the miR-200 family and the EMT-associated transcription factors ZEB1 and SNAI1, suggesting that cSCC EMT dynamics are regulated in a miRNA-dependent manner. These novel findings in cSCC tumors provide evidence of phenotypic plasticity of the EMT process occurring within patient tissues, and extend the characterization of a hybrid EMT program occurring within a tumor mass. This hybrid EMT program may be promoting both survival and invasiveness of the tumors. A better understanding of this hybrid EMT process may influence therapeutic strategies in more invasive disease.

Verified
Journal Article
Open access
PDF file
CUChandana Uppalapati
Chandana Uppalapati
MJMarquise Antone Jeffery
Marquise Antone Jeffery
APAgnes S. Pascual
Agnes S. Pascual
EHElizabeth Hull
Elizabeth Hull
KLKathryn J. Leyva
Kathryn J. Leyva
Collective cell migration (CCM) is a coordinated process involving cell–cell and cell–environment interactions occurring in many physiological systems, including development, wound healing, and metastasis. Using zebrafish keratocytes as a wound healing model provides a unique system to investigate the interplay of matrix metalloproteinases (MMPs) in CCM. MMPs play an important role in CCM as they generate bioactive molecules that regulate proliferation, differentiation, angiogenesis, apoptosis, and cell migration. Secreted as pro-enzymes, MMPs must be activated, frequently by another MMP. As a group, MMPs have been reported to have a pro-migratory role during CCM, yet our data reveal that one MMP, MMP13, is not pro-migratory. Treatment of keratocytes with recombinant MMP13 resulted in a dose-dependent decrease in migration, reduced MMP13 activity, and increased MMP9 mRNA expression. Treatment with an MMP13-specific inhibitor resulted in a dose-dependent increase in migration with no change in the rate of cellular proliferation, an increase in total MMP activity, and increased MMP2 mRNA expression. Similarly, inhibition of MMP14 also resulted in a significant, dose-dependent decrease in migration. However, MMP14 inhibition resulted in both an increase in MMP2 mRNA expression and a decrease in MMP9 mRNA expression. The increase in MMP2 and/or MMP9 activity was observed on gel zymography for both treatments. Our data support the hypothesis that MMP13 is anti-migratory while MMP2, MMP9 and MMP14 have a pro-migratory effect on zebrafish keratocytes. Taken together, our results outline a novel inhibitory role for MMP regulation of CCM that has implications for many other processes in multicellular organisms.